The Technical Analyst
Achieve Life Sciences Inc [ACHV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Achieve Life Sciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.77% $4.58
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 156.70 mill |
| EPS: | -1.500 |
| P/E: | -3.05 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 34.25 mill |
| Avg Daily Volume: | 0.0948 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.05 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.52x |
| Company: PE -3.05 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0598 (-101.31%) $-4.63 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.34 - 4.82 ( +/- 5.28%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-19 | Wan Jerry | Buy | 5 625 | Common Stock |
| 2024-04-19 | Wan Jerry | Sell | 2 250 | Common Stock |
| 2024-04-19 | Wan Jerry | Sell | 5 625 | Performance Restricted Stock Unit (PRSU) |
| 2024-04-19 | Jacobs Cindy | Buy | 16 250 | Common Stock |
| 2024-04-19 | Jacobs Cindy | Sell | 3 957 | Common Stock |
| INSIDER POWER |
|---|
| 80.14 |
| Last 96 transactions |
| Buy: 1 756 760 | Sell: 148 618 |
Forecast:
16:00 - $4.59
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.59
Forecast 2: 16:00 - $4.59
Forecast 3: 16:00 - $4.59
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.58 (0.77% ) |
| Volume | 0.0566 mill |
| Avg. Vol. | 0.0948 mill |
| % of Avg. Vol | 59.71 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACHV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ACHV
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Last 10 Buy Signals
Latest Press Releases
2024-04-25 08:00:00 - Press Release
Achieve Life Sciences To Announce First Quarter Financial Results And Host Conference Call And Webcast On May 9, 2024
Seattle and vancouver, british columbia, april 25, 2024 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on thursday, may 9, 2024, at 4:30 pm edt.
2024-03-28 16:01:00 - Press Release
Achieve Life Sciences Reports Financial Results For Fourth Quarter And Year-end 2023 And Provides Corporate Update
Company to host conference call at 4:30 pm edt today, thursday, march 28, 2024 company to host conference call at 4:30 pm edt today, thursday, march 28, 2024
2024-03-06 08:00:00 - Press Release
Achieve Life Sciences Announces Participation At Upcoming Investor Conferences
Seattle and vancouver, british columbia, march 06, 2024 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that achieve management will be participating in the following upcoming investor conferences.
2024-02-29 08:01:00 - Press Release
Achieve Life Sciences Reaches Agreement With The Fda On Long-term Cytisinicline Exposure Data Requirements For Nda Submission
Open-label exposure trial expected to initiate in q2'24 with nda filing anticipated in 1h 2025 open-label exposure trial expected to initiate in q2'24 with nda filing anticipated in 1h 2025
2024-02-29 08:00:00 - Press Release
Achieve Life Sciences Announces Pricing Of Up To $124.2 Million Registered Direct Offering And Concurrent Private Placement
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants
Latest News
2024-04-25 08:00:00 - GlobeNewsWire
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT.
2024-04-04 06:30:32 - Seeking Alpha
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns
Achieve Life Sciences is working to commercialize the smoking cessation drug Cytisinicline, which has shown promising results in clinical trials. The drug has a superior safety profile compared to existing treatment options and has the potential to address a large market. The company is expected to be sold to a larger entity in 2025, with potential returns of 4-9x for investors.
2024-03-28 21:03:08 - Seeking Alpha
Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
2024-03-06 08:00:00 - GlobeNewsWire
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences.
2023-12-12 09:10:26 - InvestorPlace
Why Is Achieve Life Sciences (ACHV) Stock Down 25% Today?
Achieve Life Sciences (NASDAQ: ACHV ) stock is dropping on Tuesday after the company provided an update on its New Drug Application (NDA) for cytisinicline. A meeting with the Food and Drug Administration (FDA) saw the agency request additional data concerning cytisinicline before it will approve its NDA.
2023-12-12 08:53:00 - Market Watch
Achieve Life Sciences shares drop as analysts see delayed launch of smoking-cessation treatment
Achieve Life Sciences Inc. shares ACHV, -1.09% dropped 25% premarket on Tuesday as analysts forecasted delays in the launch of the company's smoking cessation treatment cytisinicline. In a recent meeting with the U.S. Food and Drug Administration, the agency said it would need longer-term data beyond 12 weeks to assess potential safety risks of cytisinicline, given that the regulator views smoking cessation drugs as products for chronic, intermittent use, Achieve Life Sciences said in a regulatory filing Monday.
2023-12-11 16:30:00 - GlobeNewsWire
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences.
2023-11-09 20:08:09 - Seeking Alpha
Achieve Life Sciences, Inc. (ACHV) Q3 2023 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Nicole Jones - IR John Bencich - CEO Jerry Wan - Principal Accounting Officer Cindy Jacobs - President and CMO Conference Call Participants Thomas Flaten - Lake Street Michael Higgins - Ladenburg Thalmann John Vandermosten - Saks Operator Greetings. Welcome to Achieve Life Sciences Third Quarter Earnings Conference Call and Webcast.
2023-10-26 08:00:00 - GlobeNewsWire
Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023
SEATTLE and VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its third quarter 2023 financial results and provide an update on the cytisinicline development program on Thursday, November 9, 2023 at 4:30 PM EST.
2023-10-03 08:00:00 - GlobeNewsWire
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that management will be participating at two upcoming investor conferences.